TTP
Advertisement: Mobas mid banner
Advertisement: Barclays Eagle Labs
Advertisement: BKL
Advertisement: Cambridge Network
Advertisement: Wild Knight Vodka
RealVNC mid banner careers
Advertisement: CPL mid banner
Advertisement: KISS
RealVNC mid-banner general
ARM Innovation Hub
Barr Ellison Solicitors – commercial property
4 February, 2018 - 10:48 By Tony Quested

US investors help take Intelligent Fingerprinting funding past £13m

Intelligent Fingerprinting, developer of the world’s first portable fingerprint drug test, has secured a further £1.7 million of funding from a group of private US and UK investors.  It has now raised £13.2m since launch.

The new cash will help accelerate commercialisation of the recently launched Intelligent Fingerprinting Drug Screening System – particularly into key UK workplace market sectors such as construction, transport, warehousing and manufacturing.

Intelligent Fingerprinting develops and manufactures its drug screening system from a dedicated facility in Cambridge. 

Chairman Philip Hand (pictured above) said: “Following the successful launch of our fingerprint drug test and our transition from successful pilot projects to commercial engagements we’re now focused on strengthening our UK sales and marketing resources as well as our international offering.

“This latest funding will see the company place increased emphasis on the critical workplace sector, and will also help support our ongoing FDA approval activities in the US.”

The technology works by analysing the sweat from a fingerprint, so – unlike traditional urine or saliva-based drug testing – it’s non-invasive, fast and cost-effective. 

By collecting and analysing tiny traces of sweat from a fingerprint, the Intelligent Fingerprinting test can detect drugs and drug metabolites in under 10 minutes. 

The system features a single-use cartridge that screens for multiple drug groups simultaneously (currently amphetamines, cannabis, cocaine and opiates), with sample collection taking just five seconds.

Since commercial launch in August 2017, the fingerprint drug test has quickly proved itself, and is already in use in the UK across a range of applications including for screening in the workplace; supporting drug recovery programmes; and to help with coroner investigations in mortuaries.

The business secured initial seed investment in 2009, followed by the first round of funding from the company’s US investors in 2012. Prior to the latest announcement, the company had raised over £11 million of private investment over six years in addition to original funding of £0.5m.

Advertisement: Barclays Eagle Labs

Newsletter Subscription

Stay informed of the latest news and features